Group 1 - The company, First Pharmaceutical, forecasts a net profit attributable to shareholders of the parent company for the year 2025 to be between 41.5 million and 62 million yuan, which represents a decrease of approximately 101 million to 122 million yuan compared to the same period last year, reflecting a year-on-year decline of 61.98% to 74.55% [1] - The decrease in net profit is primarily attributed to the presence of housing expropriation compensation in the same period last year [1] Group 2 - The silver market has seen a surge of over 80% in the last 50 days, indicating a level of enthusiasm that surpasses that of gold, suggesting that the current silver boom may signal a peak in the precious metals bull market [1]

证券代码：600833 证券简称：第一医药 公告编号：2026-002 上海第一医药股份有限公司 关于使用闲置自有资金进行委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： 基本情况 | 投资金额 | 总额度不超过人民币 | 30,000 万元（含 30,000 万元） | | --- | --- | --- | | 投资种类 | 风险等级为 R2 | 及以下的固收类理财产品 | | 资金来源 | 自有资金 | | 已履行的审议程序 本次委托理财已经上海第一医药股份有限公司（以下简称"公司"）2026 年 1 月 16 日召开的第十一届董事会第七次（临时）会议审议通过，本次委托理财额度在公司董事 会决策权限范围内，无需提交股东会审议。 特别风险提示 本次购买的委托理财产品属于固收类产品，公司将根据经济形势以及金融市场的变 化适时、适量进行相关事宜的推进。但金融市场受宏观经济、财政政策、货币政策的影 响较大，不排除公司投资理财产品可能受到市场波动及相关风险因素的影响，委托理财 的实际收益存在不确定性 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 41.5 million and 62 million yuan, representing a decrease of 10.10613 million to 12.15613 million yuan compared to the previous year, a year-on-year decline of 61.98% to 74.55%[4] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 4.9 million and 7.3 million yuan, with a potential decrease of 197.4 thousand yuan to an increase of 42.6 thousand yuan compared to the previous year, reflecting a year-on-year change of -28.72% to +6.20%[4] - In the previous year, the company achieved a total profit of 216.2713 million yuan and a net profit attributable to shareholders of the parent company of 163.0613 million yuan[6] - The decrease in net profit is primarily attributed to the presence of housing expropriation compensation in the previous year's results[7] - The earnings per share for the previous year was 0.73 yuan[6] Earnings Forecast Details - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[8] - The company emphasizes that there are no significant uncertainties affecting the accuracy of this earnings forecast[8] - Investors are advised to make cautious decisions and be aware of investment risks[4] - The data provided in the earnings forecast is preliminary and the final financial data will be disclosed in the company's official 2025 annual report[9] - The earnings forecast period is from January 1, 2025, to December 31, 2025[4]

Group 1: Company Innovations - The "氛子药局" is a new store by the 72-year-old brand, 第一医药, which combines traditional medicine with modern aesthetics, attracting a younger demographic [1] - The store features a unique design with a "day coffee, night bar" concept, transforming from a health drink space during the day to a social venue at night, while traditional medicine sales are located on the second floor [1] - The store has exceeded expectations in terms of customer traffic and sales within the first month of operation [1] Group 2: Market Trends - Young consumers are increasingly valuing experiential offerings, leading to a shift in how traditional brands like 第一医药 engage with their audience [2] - The restaurant industry in Shanghai is seeing a surge in new openings, with 498 new dining establishments launched by October last year, indicating a strong growth in the first-store economy [2] - The introduction of innovative dining experiences, such as the immersive dining experience led by a virtual chef, highlights the growing demand for unique culinary experiences among both domestic and international tourists [3][4] Group 3: Consumer Behavior - The average daily booking volume for the new restaurant concept is continuously increasing, with a significant portion of customers being international tourists [4] - The integration of cultural elements into dining experiences is enhancing the appeal of Shanghai as a culinary destination, attracting more visitors and encouraging further expansion into other cities [4]

Core Viewpoint - The article discusses the innovative transformation of traditional pharmacies into lifestyle and health-oriented spaces, exemplified by "Fenzi Pharmacy," which integrates health, beauty, and lifestyle elements to attract a younger demographic [2][3][21]. Group 1: Transformation of Pharmacy Concept - "Fenzi Pharmacy" redefines the traditional pharmacy model by creating a mixed space that combines health, beauty, and lifestyle, appealing to urban health-conscious consumers, particularly the younger generation [3][9]. - The store layout is divided into two levels, with the first floor resembling a trendy lifestyle store featuring a tea drink bar and beauty product displays, while the second floor retains traditional pharmacy functions but with modern upgrades [6][7]. - The pharmacy aims to attract a new customer base by offering a variety of health-oriented beverages and beauty products, thus transforming the shopping experience from a purely transactional one to a more engaging and social environment [9][10]. Group 2: Customer Engagement and Experience - The pharmacy's strategy focuses on attracting young consumers by providing a casual and social atmosphere, including a tea drink bar that serves health-oriented beverages, which aligns with the lifestyle habits of the target demographic [9][10]. - The integration of health solutions and beauty products into a cohesive shopping experience allows consumers to find comprehensive solutions for their health and beauty needs, enhancing customer engagement [10][12]. - The store's design and marketing strategies, such as festive decorations and social media engagement, create a welcoming environment that encourages customers to visit frequently and interact with staff for personalized advice [18][20]. Group 3: Market Trends and Industry Challenges - The shift towards integrating beauty and health reflects a broader change in consumer behavior, where young consumers prioritize proactive health management and emotional well-being over traditional illness treatment [25][30]. - The pharmacy's transformation is a response to the declining profitability of traditional pharmacies due to policy changes and evolving consumer demands, necessitating a shift towards non-pharmaceutical products to ensure survival [21][22]. - The article highlights the need for pharmacies to adapt to changing market dynamics by focusing on community and lifestyle integration rather than solely on pharmaceutical sales, indicating a significant shift in retail strategies [32][33].

证券日报网讯12月29日，第一医药（600833）在互动平台回答投资者提问时表示，根据公司2025年第三 季度报告及相关资料，公司资产处置收益本期为4960.83万元，去年同期为1.41亿元，同比大幅下降的主 要原因在于：上年同期公司及子公司收到房屋征收补偿款，而本期该项收益减少。 ...

Core Viewpoint - The article discusses the increasing role of the Investor Protection Center in nominating independent directors for listed companies, enhancing the voice of small and medium shareholders in corporate governance [1][4][8]. Group 1: Independent Director Nomination - The Investor Protection Center has publicly nominated independent director candidates and collected voting rights for four companies: First Pharmaceutical, Shangfeng Cement, South Network Energy, and Xinbo Co., indicating a shift towards active participation in corporate governance [1][3][8]. - The nomination of Zhang Lizhi as an independent director for South Network Energy was successfully approved, with 9 valid shareholders authorizing the center to exercise voting rights, representing approximately 0.0422% of the total voting shares [3][8]. - The center's approach allows for a more diverse selection of independent directors, enhancing their independence and professionalism, which is crucial for representing the interests of small shareholders [5][6]. Group 2: Enhancing Shareholder Rights - The initiative aims to strengthen the voice of small shareholders, who traditionally have low participation in corporate governance, often resorting to "voting with their feet" [4][6]. - By publicly nominating independent directors and collecting voting rights, the center facilitates small investors in exercising their voting rights, creating a positive example for active participation in corporate governance [4][5]. - The center's actions are seen as a beneficial attempt to address the weak voice of small shareholders and improve the overall effectiveness of investor rights protection [5][6]. Group 3: Full Chain Rights Protection Mechanism - The nomination process contributes to a comprehensive rights protection mechanism, addressing preemptive measures in addition to existing shareholder rights and securities litigation [6][8]. - The center's involvement allows independent directors to participate directly in major corporate decisions, enhancing preventive measures against potential governance issues [6][7]. - The initiative reflects a broader trend of investor protection agencies transitioning from peripheral supporters to active participants in corporate governance structures [6][7]. Group 4: Challenges and Recommendations - Despite the positive developments, the current mechanism faces challenges, including limited case studies and low shareholder participation rates [8][9]. - Experts suggest improving awareness among small shareholders regarding the nomination process and simplifying the authorization procedures to encourage greater participation [9][10]. - There is a need for ongoing efforts to establish a replicable framework across various industries and companies to enhance market recognition and gradually increase the influence of this mechanism [9][10].

Group 1 - The pharmacy sector experienced a short-term decline, with stocks such as Shuyupingmin falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, also saw a drop in their stock prices [1]

Group 1 - The pharmacy sector has experienced a short-term decline, with major companies such as Xu Yu Ping Min falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, have also seen declines in their stock prices [1]

2025 年 12 月 5 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于召开 2025 年第三季度业绩说明会的公告》（公告编号：临 2025-051）。 公司党委书记、董事长张海波先生，党委副书记、副董事长、总经理姚军先 生，独立董事汪丰先生、唐松莲女士、陈少雄先生以及董事会秘书、财务总监孙 峥先生出席了本次说明会，就公司 2025 年第三季度的经营成果及财务指标等情 况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者关注的问题 进行了回复。 证券代码：600833 证券简称：第一医药 公告编号：临 2025-052 上海第一医药股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海第一医药股份有限公司（以下简称"公司"）2025 年第三季度业绩说 明会于 2025 年 12 月 12 日（星期五）下午 15:00-16:00 通过上海证券交易所上 证路演中心（网址：https://roadshow.sseinfo.com/ ...